Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors

Yuqiong Liang, Hisashi Ishida, Oliver Lenz, Tse I. Lin, Origène Nyanguile, Kenny Simmen, Richard Pyles, Nigel Bourne, Min Kyung Yi, Kui Li, Stanley M. Lemon

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background & Aims: Expression of the nonstructural protein (NS)3/4A protease in cells infected with hepatitis C virus (HCV) results in cleavage of the mitochondrial antiviral-signaling protein (MAVS) and disruption of signaling pathways that lead to viral activation of interferon regulatory factor 3 (IRF-3) and synthesis of type 1 interferons (IFN-α/β). High concentrations of inhibitors of NS3/4A reverse this signaling defect, but quantitative analyses of this potential therapeutic effect are lacking. This study quantitatively assessed the rescue of IRF-3 signaling by NS3/4A inhibitors, compared with in vitro antiviral activity. Methods: Antiviral activities of 2 NS3/4A protease inhibitors (TMC435350 and an analog, TMC380765) and a nonnucleoside polymerase inhibitor (Tib-3) were determined in HCV replicon cells and in cells infected with genotype 1a and 2a viruses. The capacity to rescue IRF-3 activation in these cells was assessed by monitoring IFN-β promoter activity following challenge with Sendai virus. Inhibitor-induced changes in NS3 and MAVS expression were assessed in immunoblots. Results: Both protease inhibitors were capable of rescuing IFN-β promoter activation but only at concentrations ∼100-fold the antiviral 50% effective concentration (EC50) for genotype 1 virus. No rescue was observed with the polymerase inhibitor, even at a concentration 600-fold greater than the EC50. IRF-3 activation did not correlate with reductions in NS3/4A levels or detection of full-length MAVS. Overexpression of the product of NS3/4A cleavage of MAVS did not result in a dominant-negative effect on signaling. Conclusions: NS3/4A protease inhibitors can restore IRF-3 signaling in HCV-infected cells but only at concentrations far in excess of the antiviral EC50.

Original languageEnglish (US)
JournalGastroenterology
Volume135
Issue number5
DOIs
StatePublished - Nov 2008

Fingerprint

Hepatitis C
Protease Inhibitors
Antiviral Agents
Interferon Regulatory Factor-3
Hepacivirus
Proteins
Genotype
Viruses
Sendai virus
Virus Activation
Interferon Type I
Replicon
Therapeutic Uses
Peptide Hydrolases

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors. / Liang, Yuqiong; Ishida, Hisashi; Lenz, Oliver; Lin, Tse I.; Nyanguile, Origène; Simmen, Kenny; Pyles, Richard; Bourne, Nigel; Yi, Min Kyung; Li, Kui; Lemon, Stanley M.

In: Gastroenterology, Vol. 135, No. 5, 11.2008.

Research output: Contribution to journalArticle

Liang, Yuqiong ; Ishida, Hisashi ; Lenz, Oliver ; Lin, Tse I. ; Nyanguile, Origène ; Simmen, Kenny ; Pyles, Richard ; Bourne, Nigel ; Yi, Min Kyung ; Li, Kui ; Lemon, Stanley M. / Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors. In: Gastroenterology. 2008 ; Vol. 135, No. 5.
@article{b07902fa0843476086259f8d8cd4bad9,
title = "Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors",
abstract = "Background & Aims: Expression of the nonstructural protein (NS)3/4A protease in cells infected with hepatitis C virus (HCV) results in cleavage of the mitochondrial antiviral-signaling protein (MAVS) and disruption of signaling pathways that lead to viral activation of interferon regulatory factor 3 (IRF-3) and synthesis of type 1 interferons (IFN-α/β). High concentrations of inhibitors of NS3/4A reverse this signaling defect, but quantitative analyses of this potential therapeutic effect are lacking. This study quantitatively assessed the rescue of IRF-3 signaling by NS3/4A inhibitors, compared with in vitro antiviral activity. Methods: Antiviral activities of 2 NS3/4A protease inhibitors (TMC435350 and an analog, TMC380765) and a nonnucleoside polymerase inhibitor (Tib-3) were determined in HCV replicon cells and in cells infected with genotype 1a and 2a viruses. The capacity to rescue IRF-3 activation in these cells was assessed by monitoring IFN-β promoter activity following challenge with Sendai virus. Inhibitor-induced changes in NS3 and MAVS expression were assessed in immunoblots. Results: Both protease inhibitors were capable of rescuing IFN-β promoter activation but only at concentrations ∼100-fold the antiviral 50{\%} effective concentration (EC50) for genotype 1 virus. No rescue was observed with the polymerase inhibitor, even at a concentration 600-fold greater than the EC50. IRF-3 activation did not correlate with reductions in NS3/4A levels or detection of full-length MAVS. Overexpression of the product of NS3/4A cleavage of MAVS did not result in a dominant-negative effect on signaling. Conclusions: NS3/4A protease inhibitors can restore IRF-3 signaling in HCV-infected cells but only at concentrations far in excess of the antiviral EC50.",
author = "Yuqiong Liang and Hisashi Ishida and Oliver Lenz and Lin, {Tse I.} and Orig{\`e}ne Nyanguile and Kenny Simmen and Richard Pyles and Nigel Bourne and Yi, {Min Kyung} and Kui Li and Lemon, {Stanley M.}",
year = "2008",
month = "11",
doi = "10.1053/j.gastro.2008.07.023",
language = "English (US)",
volume = "135",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors

AU - Liang, Yuqiong

AU - Ishida, Hisashi

AU - Lenz, Oliver

AU - Lin, Tse I.

AU - Nyanguile, Origène

AU - Simmen, Kenny

AU - Pyles, Richard

AU - Bourne, Nigel

AU - Yi, Min Kyung

AU - Li, Kui

AU - Lemon, Stanley M.

PY - 2008/11

Y1 - 2008/11

N2 - Background & Aims: Expression of the nonstructural protein (NS)3/4A protease in cells infected with hepatitis C virus (HCV) results in cleavage of the mitochondrial antiviral-signaling protein (MAVS) and disruption of signaling pathways that lead to viral activation of interferon regulatory factor 3 (IRF-3) and synthesis of type 1 interferons (IFN-α/β). High concentrations of inhibitors of NS3/4A reverse this signaling defect, but quantitative analyses of this potential therapeutic effect are lacking. This study quantitatively assessed the rescue of IRF-3 signaling by NS3/4A inhibitors, compared with in vitro antiviral activity. Methods: Antiviral activities of 2 NS3/4A protease inhibitors (TMC435350 and an analog, TMC380765) and a nonnucleoside polymerase inhibitor (Tib-3) were determined in HCV replicon cells and in cells infected with genotype 1a and 2a viruses. The capacity to rescue IRF-3 activation in these cells was assessed by monitoring IFN-β promoter activity following challenge with Sendai virus. Inhibitor-induced changes in NS3 and MAVS expression were assessed in immunoblots. Results: Both protease inhibitors were capable of rescuing IFN-β promoter activation but only at concentrations ∼100-fold the antiviral 50% effective concentration (EC50) for genotype 1 virus. No rescue was observed with the polymerase inhibitor, even at a concentration 600-fold greater than the EC50. IRF-3 activation did not correlate with reductions in NS3/4A levels or detection of full-length MAVS. Overexpression of the product of NS3/4A cleavage of MAVS did not result in a dominant-negative effect on signaling. Conclusions: NS3/4A protease inhibitors can restore IRF-3 signaling in HCV-infected cells but only at concentrations far in excess of the antiviral EC50.

AB - Background & Aims: Expression of the nonstructural protein (NS)3/4A protease in cells infected with hepatitis C virus (HCV) results in cleavage of the mitochondrial antiviral-signaling protein (MAVS) and disruption of signaling pathways that lead to viral activation of interferon regulatory factor 3 (IRF-3) and synthesis of type 1 interferons (IFN-α/β). High concentrations of inhibitors of NS3/4A reverse this signaling defect, but quantitative analyses of this potential therapeutic effect are lacking. This study quantitatively assessed the rescue of IRF-3 signaling by NS3/4A inhibitors, compared with in vitro antiviral activity. Methods: Antiviral activities of 2 NS3/4A protease inhibitors (TMC435350 and an analog, TMC380765) and a nonnucleoside polymerase inhibitor (Tib-3) were determined in HCV replicon cells and in cells infected with genotype 1a and 2a viruses. The capacity to rescue IRF-3 activation in these cells was assessed by monitoring IFN-β promoter activity following challenge with Sendai virus. Inhibitor-induced changes in NS3 and MAVS expression were assessed in immunoblots. Results: Both protease inhibitors were capable of rescuing IFN-β promoter activation but only at concentrations ∼100-fold the antiviral 50% effective concentration (EC50) for genotype 1 virus. No rescue was observed with the polymerase inhibitor, even at a concentration 600-fold greater than the EC50. IRF-3 activation did not correlate with reductions in NS3/4A levels or detection of full-length MAVS. Overexpression of the product of NS3/4A cleavage of MAVS did not result in a dominant-negative effect on signaling. Conclusions: NS3/4A protease inhibitors can restore IRF-3 signaling in HCV-infected cells but only at concentrations far in excess of the antiviral EC50.

UR - http://www.scopus.com/inward/record.url?scp=55249124522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249124522&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2008.07.023

DO - 10.1053/j.gastro.2008.07.023

M3 - Article

VL - 135

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -